Welcome to the official InxMed website
学术文献

学术文献

>
发表文献
Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling
Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling
Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling.
Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling.
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
Focal adhesion kinase inhibitors, a heavy punch to cancer
Focal adhesion kinase inhibitors, a heavy punch to cancer
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
上一页
1
 InxMed

我们致力于开发针对肿瘤耐药和转移的创新疗法

快速链接

联系我们

电话: 025-58251030
邮箱: office@inxmed.com
公司地址: 南京市江北新区探秘路73号树屋十六栋D-2栋3层

在线留言

关注我们:

CopyRight © 2022 应世生物 All Rights Reserved.

网站建设: 中企动力 苏州